Zobrazeno 1 - 10
of 104
pro vyhledávání: '"Raffael, Nachbagauer"'
Autor:
Carly M. Bliss, Raffael Nachbagauer, Chiara Mariottini, Frans Cuevas, Jodi Feser, Abdi Naficy, David I. Bernstein, Jeffrey Guptill, Emmanuel B. Walter, Francesco Berlanda-Scorza, Bruce L. Innis, Adolfo García-Sastre, Peter Palese, Florian Krammer, Lynda Coughlan
Publikováno v:
EBioMedicine, Vol 104, Iss , Pp 105153- (2024)
Summary: Background: The development of a universal influenza virus vaccine, to protect against both seasonal and pandemic influenza A viruses, is a long-standing public health goal. The conserved stalk domain of haemagglutinin (HA) is a promising va
Externí odkaz:
https://doaj.org/article/c9ca6df22ec740d499055ef8fed469f9
Autor:
Ivan T. Lee, Raffael Nachbagauer, David Ensz, Howard Schwartz, Lizbeth Carmona, Kristi Schaefers, Andrei Avanesov, Daniel Stadlbauer, Carole Henry, Ren Chen, Wenmei Huang, Daniela Ramirez Schrempp, Jintanat Ananworanich, Robert Paris
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-11 (2023)
Abstract Despite vaccine availability, influenza remains a substantial global public health concern. Here, we report interim findings on the primary and secondary objectives of the safety, reactogenicity, and humoral immunogenicity of a quadrivalent
Externí odkaz:
https://doaj.org/article/234959adb1584b539256d7f99380c3d4
Autor:
Colin A. Russell, Ron A. M. Fouchier, Parinaz Ghaswalla, Yoonyoung Park, Nevena Vicic, Jintanat Ananworanich, Raffael Nachbagauer, Deborah Rudin
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
ABSTRACTInfluenza remains a public health threat, partly due to suboptimal effectiveness of vaccines. One factor impacting vaccine effectiveness is strain mismatch, occurring when vaccines no longer match circulating strains due to antigenic drift or
Externí odkaz:
https://doaj.org/article/6a73d975b6bf4fc69c8881c1d8d5e4bf
Autor:
Alec W. Freyn, Matthew Pine, Victoria C. Rosado, Marcel Benz, Hiromi Muramatsu, Mitchell Beattie, Ying K. Tam, Florian Krammer, Peter Palese, Raffael Nachbagauer, Meagan McMahon, Norbert Pardi
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 22, Iss , Pp 84-95 (2021)
Nucleoside-modified, lipid nanoparticle-encapsulated mRNAs have recently emerged as suitable vaccines for influenza viruses and other pathogens in part because the platform allows delivery of multiple antigens in a single immunization. mRNA vaccines
Externí odkaz:
https://doaj.org/article/170090d7563642ec8a6592c47132c75d
Autor:
Daniel Stadlbauer, Leon de Waal, Edith Beaulieu, Shirin Strohmeier, Edwin J. B. Veldhuis Kroeze, Philippe Boutet, Albert D. M. E. Osterhaus, Florian Krammer, Bruce L. Innis, Raffael Nachbagauer, Koert J. Stittelaar, Corey P. Mallett
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-10 (2021)
Abstract Human infections with avian H7N9 subtype influenza viruses are a major public health concern and vaccines against H7N9 are urgently needed for pandemic preparedness. In early 2013, novel H7N9 influenza viruses emerged in China that caused ab
Externí odkaz:
https://doaj.org/article/1f961e1904734a6b881c4f9a5ecc6653
Autor:
Carly M. Bliss, Andrea J. Parsons, Raffael Nachbagauer, Jennifer R. Hamilton, Federica Cappuccini, Marta Ulaszewska, Jason P. Webber, Aled Clayton, Adrian V.S. Hill, Lynda Coughlan
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 16, Iss , Pp 108-125 (2020)
Adenoviral (Ad) vectors represent promising vaccine platforms for infectious disease. To overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5), vectors based on rare species or non-human Ads are being developed. However, t
Externí odkaz:
https://doaj.org/article/cd6a0c58b0e84b3aad7a70894ddac5d1
Autor:
Wafaa B. Alsoussi, Sameer Kumar Malladi, Julian Q. Zhou, Zhuoming Liu, Baoling Ying, Wooseob Kim, Aaron J. Schmitz, Tingting Lei, Stephen C. Horvath, Alexandria J. Sturtz, Katherine M. McIntire, Birk Evavold, Fangjie Han, Suzanne M. Scheaffer, Isabella F. Fox, Senaa F. Mirza, Luis Parra-Rodriguez, Raffael Nachbagauer, Biliana Nestorova, Spyros Chalkias, Christopher W. Farnsworth, Michael K. Klebert, Iskra Pusic, Benjamin S. Strnad, William D. Middleton, Sharlene A. Teefey, Sean P. J. Whelan, Michael S. Diamond, Robert Paris, Jane A. O’Halloran, Rachel M. Presti, Jackson S. Turner, Ali H. Ellebedy
Publikováno v:
Nature. 617:592-598
Autor:
Philip Meade, Guillermina Kuan, Shirin Strohmeier, Hannah E. Maier, Fatima Amanat, Angel Balmaseda, Kimihito Ito, Ericka Kirkpatrick, Andres Javier, Lionel Gresh, Raffael Nachbagauer, Aubree Gordon, Florian Krammer
Publikováno v:
mBio, Vol 11, Iss 1 (2020)
ABSTRACT In contrast to influenza virus vaccination, natural infection induces long-lived and relatively broad immune responses. However, many aspects of the antibody response to natural infection are not well understood. Here, we assessed the immune
Externí odkaz:
https://doaj.org/article/8949058e563642218bd96502680e85f1
Autor:
Raquel Muñoz-Moreno, Carles Martínez-Romero, Daniel Blanco-Melo, Christian V. Forst, Raffael Nachbagauer, Asiel Arturo Benitez, Ignacio Mena, Sadaf Aslam, Vinod Balasubramaniam, Ilseob Lee, Maryline Panis, Juan Ayllón, David Sachs, Man-Seong Park, Florian Krammer, Benjamin R. tenOever, Adolfo García-Sastre
Publikováno v:
Cell Reports, Vol 29, Iss 12, Pp 3997-4009.e5 (2019)
Summary: Influenza A viruses (IAVs) have a remarkable tropism in their ability to circulate in both mammalian and avian species. The IAV NS1 protein is a multifunctional virulence factor that inhibits the type I interferon host response through a myr
Externí odkaz:
https://doaj.org/article/310a10bd7e19493ba91d29671dbcdea0
Autor:
Nicolas Folschweiller, Carline Vanden Abeele, Laurence Chu, Pierre Van Damme, Adolfo García-Sastre, Florian Krammer, Raffael Nachbagauer, Peter Palese, Alicia Solórzano, Dan Bi, Marie-Pierre David, Damien Friel, Bruce L Innis, Juliane Koch, Corey P Mallett, Ronan Nicolas Rouxel, Bruno Salaun, Valerie Vantomme, Céline Verheust, Frank Struyf
Publikováno v:
The lancet infectious diseases
Background One strategy to develop a universal influenza virus vaccine is to redirect the immune system to the highly conserved haemagglutinin stalk domain by sequentially administering vaccines expressing chimeric (c) haemagglutinins with a conserve